Jenex Signs Exclusive License Agreement with Luminar Media Group Inc. for USD $250,000 for Jenex's Next Generation Thermal Therapy Insect Device

Toronto, Ontario--(Newsfile Corp. - November 3, 2016) - THE JENEX CORPORATION (TSXV: JEN.H) ("Jenex" or the "Corporation"), Rob Fia, CEO and Chairman of Jenex, reports the Corporation has entered into an exclusive license agreement (the "License") with Luminar Media Group Inc. of Aventura, Florida to market Jenex's next generation thermal therapy insect device (the "Device"). Luminar has an extensive contact base with Over the Counter ("OTC") retail distribution channels in the US. Europe and Asia. The License is subject to TSX Venture Exchange approval.

The License allows Luminar the exclusive right to market the Device in all markets outside of Canada including the United States, Europe and Asia. Jenex maintains the marketing rights for the Canadian market and will own all intellectual property related to the Device. Jenex is investigating various names to identify the Device and a trademark. The Device will incorporate a proprietary silver anti-microbial coating along with other new features. As previously announced, Jenex is working with Microbonds Inc., an advanced coatings and electrical design company, to complete the design of the Device. Jenex expects to have a working Device prototype in the next 30-45 days.

Jenex is pleased to announce it has received an initial USD $25,000 as outlined in the License, which includes the following additional milestone payments:

Jenex will receive a royalty payment equal to 10% of gross sales of the Device up to the first 100,000 units sold and 5% of gross sales of the Device thereafter. The royalty is payable quarterly. Luminar must meet minimum sales targets of 10,000 units sold in the first 12 months from signing the License, 50,000 units sold by 24 months following the signing of the License and 100,000 units sold by 36 months from signing of the License. Luminar must continue to sell a minimum of 100,000 units per year beyond 36 months from signing of the License.

In exchange for the above milestone and royalty payments Jenex will commit to obtaining all regulatory approvals with the FDA and other regulatory requirements in jurisdictions outside of the U.S. deemed necessary to market the product. Jenex will use its current FDA license for its former thermal therapy insect device and intends to apply for a Class II medical device that is indicated for the relief of the pain, itch, and inflammation from over 20,000 different insect stings and bites including bees, wasps, hornets, mosquitoes, black flies, and jelly fish. Jenex received approval for the above claims from the FDA (United States) in 1997. Jenex will utilize its ISO 13485 Quality Management System in any market that Luminar intends to market.

Rob Fia, CEO & Chairman of The Jenex Corporation comments:

"We are pleased to be partnering with Luminar to market our new Device. We believe our next generation product will be revolutionary and rewarding for both companies. This License is an exciting development for our Company and shareholders and is due to 'Outside the Box' thinking at Luminar and all the hard work of our staff and valuable partners that have contributed to date. We will have more to report as we work towards finalizing a working prototype of the Device."

Chris Cook, Chairman of Luminar comments: 

"We are very excited about our new partnership with The Jenex Corporation.  The license agreement is an excellent opportunity for Luminar to increase shareholder value by leveraging Jenex's unique thermal therapy device.  Luminar will bring specialized expertise in marketing and digital media capabilities to the partnership with Jenex as we expand globally with this important new treatment device."

About Jenex:

Jenex is a progressive medical device technology company focused on providing consumers with quality medical devices that address their dermatological needs.  Clear and healthy skin for all is at the core of Jenex's philosophy as is the belief that such outcomes should not be a privilege for only those who can afford costly procedures and treatments.  The Company's breakthrough proprietary thermal therapy technology uses heat and light energy to deliver effective, non-invasive and pain free skin care. The Jenex Corporation trades on the NEX (TSXV: JEN.H). For more information visit: www.thejenexcorporation.com or www.interceptcs.com

About Luminar:

The Luminar Media Group has extensive knowledge and experience in the media, marketing and entertainment industries.  Our company was started by entrepreneurs that have a vision to identify new tools to communicate with the audience.  Our presence is a natural response to a new way of working in a changing landscape. At Luminar, we embrace the challenge of the constantly evolving business landscape and our determined culture will develop solutions that evolve with the changing business paradigm. For more information contact us at Luminar Media Group Investor Relations, ir@gdee.rocks or visit us at www.gdee.rocks

Forward Looking Statements

This press release contains forward-looking statements. More particularly, this press release contains statements which include the timing of the proposed Device prototype and the commitment of Jenex to obtain all regulatory approvals with the FDA and other regulatory requirements in jurisdictions outside the US. The forward-looking statements are based on certain expectations and assumptions made by Jenex. Although Jenex believes that those expectations and assumptions are reasonable, undue reliance should not be placed on the forward-looking statements because Jenex can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those anticipated due to a number of factors and risks. In addition to other risks, there is a risk that the development of the Device prototype and the obtaining of regulatory approvals with the FDA and other regulatory requirements will be delayed. The forward-looking statements contained in this press release are made as of the date hereof. Jenex disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required under applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For Further information please contact:

The Jenex Corporation

Rob Fia
CEO & Chairman
Phone:     (416) 722-4994
e-mail: rfia@thejenexcorporation.com

NOT FOR DISSEMINATION OR DISTRIBUTION IN THE UNITED STATES